Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Daniel F. Argolo"'
O câncer de mama masculino (CMM) é uma doença rara, representando menos de 1% de todos os carcinomas mamários. O risco de desenvolver o câncer de mama é de cerca de um para 1 mil nos homens, enquanto é aproximadamente um para oito nas mulheres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f6d5df27e60386c53307165dfc87b7b
https://doi.org/10.56271/978.85.8400.124.8-12
https://doi.org/10.56271/978.85.8400.124.8-12
Autor:
Leandro Carvalho Oliveira, Thais Baccili Cury Megid, Daniela Dornelles Rosa, Carlos Alberto da Silva Magliano, Daniele Assad Suzuki, Daniel F. Argolo, Solange Moraes Sanches, Laura Testa, Jose Bines, Rafael Alioska Kaliks, Maira Caleffi, Debora De Melo Gagliato, Marina Sahade, Romualdo Barroso-Sousa, Tatiana Strava Correa, Andrea Shimada, Artur Katz, Max S. Mano
Publikováno v:
Journal of Clinical Oncology. 40:e18822-e18822
e18822 Background: Oncotype DX (ODX) is a validated tool for the prediction of risk of recurrence and benefit of chemotherapy (CH) in both node negative (N0) and positive (N1), hormone receptor positive (HR+), HER2 negative (HER2-) early breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a6c3e65a67ed736b7732b5933d2dcc7
https://doi.org/10.1200/jco.2022.40.16_suppl.e18822
https://doi.org/10.1200/jco.2022.40.16_suppl.e18822
Autor:
Monica Fornier, K Jack, Maura N. Dickler, Shanu Modi, Gary A. Ulaner, Clifford A. Hudis, L.M. Smyth, Daniel F. Argolo, Chau T. Dang, Larry Norton, Shari Goldfarb, TA Traina, Tiffany A. Troso-Sandoval, Maxine S. Jochelson, Patricia DeFusco, Ayca Gucalp, Neil M. Iyengar, D. Lake, Komal Jhaveri, Jasmeet Chadha Singh, J. Baselga
Publikováno v:
Cancer Research. 77:P4-21
Background: The combination of taxanes with trastuzumab (H) and pertuzumab (P) for first line treatment of HER2-positive metastatic breast cancer (MBC) is associated with improved progression-free survival (PFS) and overall survival (OS). Treatment p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc8da711ada4de79a024f322bea4c875
https://doi.org/10.1158/1538-7445.sabcs16-p4-21-34
https://doi.org/10.1158/1538-7445.sabcs16-p4-21-34
Autor:
Anita Mamtani, L.M. Smyth, Lee W. Jones, Larry Norton, Anthony F. Yu, Clifford A. Hudis, Camilla Boafo, Andrea V. Barrio, Steven Sugarman, Sujata Patil, Monica Morrow, José Baselga, Shanu Modi, Chau T. Dang, Sarah J. Schweber, Daniel F. Argolo, Jasmeet Chadha Singh
Publikováno v:
The Oncologist. 22:139-143
Objectives Trastuzumab (H) and pertuzumab (P) with standard chemotherapy is approved for use in the neoadjuvant setting for human epidermal growth receptor 2 -positive patients. A retrospective analysis was performed of patients treated with dose-den
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4454192a5ba4d0f71f113b765618453
https://doi.org/10.1634/theoncologist.2016-0268
https://doi.org/10.1634/theoncologist.2016-0268
Autor:
Sarah J. Schweber, Anthony F. Yu, Daniel F. Argolo, Lee W. Jones, L.M. Smyth, J. Baselga, Neil M. Iyengar, Clifford A. Hudis, Camilla Boafo, Jasmeet Chadha Singh, S. Patil, Chau T. Dang, Steven Sugarman, Shanu Modi, Larry Norton
Publikováno v:
Cancer Research. 76:P1-14
Background: Trastuzumab and pertuzumab (HP) with standard chemotherapy is approved for use in the neoadjuvant setting. We performed a retrospective analysis of patients (pts) treated with dose-dense doxorubicin and cyclophosphamide (AC) → paclitaxe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5273d11d573e332e074b6b4c36494603
https://doi.org/10.1158/1538-7445.sabcs15-p1-14-17
https://doi.org/10.1158/1538-7445.sabcs15-p1-14-17
Autor:
J. Baselga, Chau T. Dang, Daniel F. Argolo, M Friedman, Larry Norton, Jasmeet Chadha Singh, Clifford A. Hudis, S. Patil, L.M. Smyth, Neil M. Iyengar
Publikováno v:
Cancer Research. 76:P4-13
Background: Dual anti-HER2 blockade with trastuzumab and pertuzumab (HP) plus chemotherapy is an effective therapy (Rx) in the 1st-line setting for HER2-positive metastatic breast cancer (MBC). Our single arm phase II study included patients (pts) tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc8726917e2e847f025772e6a00b94c3
https://doi.org/10.1158/1538-7445.sabcs15-p4-13-20
https://doi.org/10.1158/1538-7445.sabcs15-p4-13-20
Publikováno v:
Current Breast Cancer Reports. 8:22-31
Obesity is a major global health problem with a rising worldwide burden. In addition to its association with several diseases, obesity is associated with increased incidence and worse prognosis for many malignances. Many possible mechanisms that cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ff76c5f601479fafc5d6ac56a06b55e
https://doi.org/10.1007/s12609-016-0200-0
https://doi.org/10.1007/s12609-016-0200-0
Publikováno v:
Current oncology reports. 20(6)
The rates of obesity are increasing worldwide and this condition is now recognized as a leading preventable cause of cancer. Several diseases are directly related to obesity, including diabetes, hypertension, atherosclerosis, stroke, musculoskeletal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c651a378995508b8d6d880fd512c3597
https://pubmed.ncbi.nlm.nih.gov/29644507
https://pubmed.ncbi.nlm.nih.gov/29644507
Publikováno v:
Indian Journal of Surgical Oncology. 6:390-398
The rates of overweight and obesity are increasing worldwide in both developed and developing countries. Obesity is a major public health problem as it is associated with many diseases, including diabetes, hypertension, dyslipidemia, atherosclerosis,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f3a869e9c8ea94b7a6df2931ed3d3cf
https://doi.org/10.1007/s13193-015-0483-z
https://doi.org/10.1007/s13193-015-0483-z
Autor:
Tiffany A. Troso-Sandoval, Melanie Chen, Neil M. Iyengar, Larry Norton, Clifford A. Hudis, S. M. Popper, S. Patil, L.M. Smyth, Tiffany A. Traina, Carolyn Wasserheit-Lieblich, Pamela Drullinsky, Jasmeet Chadha Singh, Elizabeth A. Comen, Chau T. Dang, Steven Sugarman, Daniel F. Argolo, Sarat Chandarlapaty, José Baselga
We previously reported progression-free survival (PFS) results on a phase II trial of weekly paclitaxel, trastuzumab, and pertuzumab in patients with human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer (MBC) treated in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebcd6da276ab9978fc7f4f297a5c3af8
https://europepmc.org/articles/PMC5017157/
https://europepmc.org/articles/PMC5017157/